Earnings per Share (EPS) of $0.01 was reported, falling below the estimated $0.08.Record quarterly service revenue of $14.9 million in Q2 2026, marking an 11% increase in total revenue to $15 million.Oncology services segment reported a profit of $7.8 million, with a margin of 52%, indicating strong performance.Champions Oncology, Inc. (NASDAQ:CSBR) is a key player in the field of translational oncology research. The company specializes in providing comprehensive research and development solutions to biopha ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $15 million, an increase of 11% year-over-year from $13.5 million in Q2 2025, driven by improved conversion of booked work due to a lower level of cancellations [8][9] - Income from operations for the quarter was $185,000, and adjusted EBITDA was approximately $800,000, with the company on track to achieve full-year positive adjusted EBITDA [8][9] - Gross margin improved to 52% compared to 45% in the previous year, supported by flat cost of sales despite increased revenue [9] Business Line Data and Key Metrics Changes - The company reported continued success in radiolabeling and radiopharmaceutical support workflows, which are expected to become a more significant part of the service offering over time [4][5] - Investments in the data platform are ongoing, enhancing its functionality and expanding utility for pharma partners, which is viewed as a critical long-term value driver [5][6] Market Data and Key Metrics Changes - The broader environment shows gradual improvement across pharma and biotech budgets, with customer engagement and opportunity pipeline generation improving relative to the previous year and a half [3] - A recent survey indicated that over a third of biotech executives plan to increase outsourcing next year, suggesting a positive trend for the company's services [15] Company Strategy and Development Direction - The company aims to deliver year-on-year revenue growth, invest in growth levers like data platforms, and maintain fiscal discipline to avoid shareholder dilution [2][3] - Focus remains on execution, maximizing conversion of existing bookings, improving operational efficiency, and advancing capabilities to distinguish the company in the market [3][7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for booking momentum in the next calendar year as R&D budgets reset for 2026 [3] - The company is encouraged by improved operational discipline, a strengthening commercial position, and strategic investments in areas with competitive advantages [7][11] Other Important Information - Corelia, a wholly-owned subsidiary focused on target discovery, is making progress in discussions with potential venture capital funding partners, with plans to redirect investment dollars toward accelerating growth in the data business once funding is secured [6] Q&A Session Summary Question: Has there been an uptick in inbound call volume regarding RFPs, and how quickly can the company return to double-digit revenue growth? - Management noted optimism regarding opportunity generation and improvements in the market, with investments in the commercial team positioning the company well for recovery [15] Question: Are sales and marketing investments targeting the data opportunity exclusively? - Management highlighted a recent hire to lead the data business, emphasizing the strategic mindset and domain expertise brought to the team, which will support both data and other services [16] Question: What are the expectations for gross margins moving forward? - Management indicated that gross margins for the service business are expected to remain in the 50%-52% range, with potential fluctuations due to various expenses [19][20] Question: Can the company provide updates on Corelia's drug candidates and potential valuations? - Management refrained from sharing specific details about Corelia but expressed excitement about the data and traction with venture capital partners [22]

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $15 million, an increase of 11% year-over-year from $13.5 million, driven by improved conversion of booked work due to a lower level of cancellations [8][9] - Income from operations for the quarter was $185,000, and adjusted EBITDA was approximately $800,000, with the company on track to achieve full-year positive adjusted EBITDA [8][9] - Gross margin improved to 52% compared to 45% last year, supported by flat cost of sales despite increased revenue [9] Business Line Data and Key Metrics Changes - The company reported continued success in radiolabeling and radiopharmaceutical support workflows, which are becoming increasingly significant in oncology drug development [4][5] - Investments in the data platform are ongoing, enhancing its functionality and expanding utility for pharma partners, which is viewed as a critical long-term value driver [5][6] Market Data and Key Metrics Changes - The broader environment shows gradual improvement across pharma and biotech budgets, with customer engagement and opportunity pipeline generation improving relative to the previous year and a half [3] - A recent survey indicated that over a third of biotech executives plan to increase outsourcing next year, suggesting a positive trend for the company's services [15] Company Strategy and Development Direction - The company aims to deliver year-on-year revenue growth, invest in growth levers like data platforms, and maintain fiscal discipline to avoid shareholder dilution [2][3] - Focus remains on execution, maximizing conversion of existing bookings, improving operational efficiency, and advancing capabilities to distinguish the company in the market [3][7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for booking momentum in the next calendar year as R&D budgets reset for 2026 [3] - The company is encouraged by improved operational discipline, a strengthening commercial position, and strategic investments in areas with competitive advantages [7][11] Other Important Information - The company ended the quarter with $8.5 million in cash and no debt, maintaining a solid financial position [10] - Corelia, a wholly-owned subsidiary focused on target discovery, is making progress in discussions with potential venture capital funding partners [6] Q&A Session Summary Question: Has there been an uptick in inbound call volume regarding RFPs, and how quickly can the company return to double-digit revenue growth? - Management noted optimism regarding opportunity generation and improvements in the market, with investments in the commercial team positioning the company well for recovery [15] Question: Are sales and marketing investments targeting the data opportunity exclusively? - Management highlighted a recent hire to lead the data business, emphasizing the strategic mindset and domain expertise brought to the team [16] Question: What are the expectations for gross margins moving forward? - Management indicated that gross margins for the service business are expected to remain in the 50%-52% range, with potential fluctuations due to various expenses [19][20] Question: Can the company provide updates on Corelia's drug candidates and potential valuations? - Management refrained from sharing specific details but expressed excitement about the data and traction with VC partners [22]

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $15 million, an increase of 11% year-over-year from $13.5 million in Q2 2025, driven by improved conversion of booked work due to a lower level of cancellations [9][10] - Gross margin improved to 52% compared to 45% in the same quarter last year, supported by operational efficiencies [10] - Adjusted EBITDA for the quarter was approximately $800,000, with income from operations at $185,000 [9][10] Business Line Data and Key Metrics Changes - The company reported continued success in radiolabeling and radiopharmaceutical support workflows, which are expected to become increasingly significant in their service offerings [4][5] - Investments in the data platform are ongoing, enhancing its functionality and expanding utility for pharma partners, which is viewed as a critical long-term value driver [5][6] Market Data and Key Metrics Changes - The broader pharma and biotech budgets are gradually improving, with customer engagement and opportunity pipeline generation showing signs of recovery [3] - A recent survey indicated that over a third of biotech executives plan to increase outsourcing next year, reflecting a positive trend in the market [15] Company Strategy and Development Direction - The company aims to deliver year-on-year revenue growth, invest in growth levers like data platforms, and maintain fiscal discipline to achieve positive Adjusted EBITDA without shareholder dilution [2][3] - The focus remains on execution, maximizing conversion of existing bookings, and improving operational efficiency [3][8] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding booking momentum as R&D budgets reset for calendar 2026, indicating a potential for improved performance in the next year [3] - The company is encouraged by its operational discipline and strategic investments in areas where it holds competitive advantages, such as its tumor bank and data platform [7][8] Other Important Information - Corelia, a wholly-owned subsidiary focused on target discovery, is making progress in discussions with potential venture capital partners, with plans to redirect investment dollars toward accelerating growth in the data business once external funding is secured [6] Q&A Session Summary Question: Has there been an uptick in inbound call volume regarding RFPs? - Management noted an improvement in opportunity generation and optimism about the market recovery, with a survey indicating increased outsourcing plans among biotech executives [15] Question: Are sales and marketing investments targeting the data opportunity exclusively? - Management highlighted a recent hire, Dr. Tamir Farid, to lead the data business, emphasizing the strategic and domain expertise he brings to enhance growth opportunities [16] Question: What are the expectations for gross margins moving forward? - Management expects gross margins for the service business to remain in the 50%-52% range, with potential fluctuations due to various expenses, including outsourced lab service costs [19][20] Question: Can you comment on the progress of Corelia's drug candidates? - Management refrained from sharing specific details but expressed excitement about the data and traction with venture capital partners, indicating that more information will be shared in the future [23]

Revenue Performance - Oncology revenue for the three months ended October 31, 2025, was $15.0 million, an increase of 11.5% from $13.5 million in the same period of 2024 [104]. - For the six months ended October 31, 2025, oncology revenue totaled $29.0 million, reflecting a 5.4% increase from $27.6 million in the prior year [104]. Expenses - Research and development expenses for the three months ended October 31, 2025, increased by approximately $927,000 or 54.9% to $2.6 million compared to $1.7 million in 2024 [111]. - Total costs and operating expenses for the three months ended October 31, 2025, were $14.9 million, a 16.4% increase from $12.8 million in the prior year [103]. - Sales and marketing expenses for the three months ended October 31, 2025, were $2.0 million, an increase of 14.1% from $1.8 million in the same period of 2024 [115]. - General and administrative expenses for the three months ended October 31, 2025, increased by $1.1 million, or 57.4%, to $3.0 million compared to $1.9 million in the same period of 2024 [116]. Net Income and Cash Flow - The company reported a net loss of $230,000 for the six months ended October 31, 2025, compared to a net income of $2.0 million for the same period in 2024 [101]. - For the six months ended October 31, 2025, net cash used in operating activities was $1.1 million, a significant decrease from net cash provided of $28,000 in the same period of 2024 [117]. - Net cash used in investing activities for the six months ended October 31, 2025, was approximately $288,000, compared to $94,000 in the same period of 2024 [118]. - Net cash provided by financing activities was $154,000 for the six months ended October 31, 2025, down from $202,000 in the same period of 2024 [119]. Financial Position - As of October 31, 2025, the company had an accumulated deficit of approximately $80.1 million and cash of $8.5 million [101]. - The company has no off-balance sheet debt or similar obligations [121]. - The company is classified as a smaller reporting company and is not required to provide additional market risk disclosures [122]. Strategic Outlook - The cost of oncology revenue for the three months ended October 31, 2025, decreased by $166,000 or 2.2% to $7.3 million compared to $7.4 million in the prior year [110]. - The company anticipates improvements in the overall cost structure as radiolabeling work transitions into its labs, which may reduce the cost of oncology revenue [110]. - The company is exploring strategic options to create additional value from its drug discovery business, including potential spin-out transactions or capital raises [100]. Accounting Policies - There have been no changes to critical accounting policies during the six months ended October 31, 2025 [120].

Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year Hackensack, NJ – December 15, 2025 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October ...

HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. ...

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - AGM Group Holdings Inc. (AGMH) increased by 185% to $6.36 [3] - AlphaVest Acquisition Corp (ATMV) rose by 77% to $26.80 [3] - Brera Holdings PLC (BREA) saw a 20% increase to $30.00 [3] - Asset Entities Inc. (ASST) gained 18% to $4.54 [3] - 22nd Century Group, Inc. (XXII) also increased by 18% to $2.08 [3] - Millennium Group International Holdings Limited (MGIH) rose by 16% to $2.84 [3] - Robo.ai Inc. (AIIO) increased by 11% to $2.17 [3] - Butterfly Network, Inc. (BFLY) saw a 10% rise to $2.10 [3] - GrafTech International Ltd. (EAF) increased by 9% to $13.91 [3] - Cardlytics, Inc. (CDLX) rose by 8% to $2.99 [3] Premarket Losers - ECD Automotive Design, Inc. (ECDA) decreased by 14% to $3.70 [4] - Champions Oncology, Inc. (CSBR) fell by 8% to $6.11 [4] - Beam Global (BEEM) saw an 8% decline to $2.79 [4] - Fathom Holdings Inc. (FTHM) decreased by 8% to $2.19 [4] - Ventyx Biosciences, Inc. (VTYX) fell by 7% to $2.20 [4] - SciSparc Ltd. (SPRC) decreased by 6% to $4.35 [4] - Lightwave Logic, Inc. (LWLG) fell by 6% to $3.45 [4] - Jasper Therapeutics, Inc. (JSPR) decreased by 6% to $2.43 [4] - StableX Technologies, Inc. (SBLX) fell by 5% to $5.67 [4] - Galecto, Inc. (GLTO) decreased by 5% to $2.70 [4]

Core Insights - Champions Oncology, Inc. (CSBR) is a significant entity in translational oncology research, focusing on advanced technologies and services to enhance cancer treatment outcomes [1] Financial Performance - For Q1 2026, CSBR reported an earnings per share (EPS) of $0.02, exceeding the estimated EPS of -$0.01, indicating strong performance [2][6] - The company's revenue for the same period was approximately $14 million, surpassing the forecast of $13.5 million, reflecting a robust start to the fiscal year [2][6] Strategic Direction - During the Q1 2026 earnings call, key executives, including CEO Robert Brainin and CFO David Miller, discussed the company's financial performance and strategic direction, attended by notable investors, showcasing confidence in CSBR's future [3] Market Valuation - CSBR has a price-to-earnings (P/E) ratio of approximately 24.28, indicating investor confidence in its earnings potential [4] - The price-to-sales ratio is about 2.57, and the enterprise value to sales ratio is around 2.48, suggesting a favorable market valuation relative to its sales [4] Financial Challenges - The company faces challenges in cash flow generation, evidenced by a negative enterprise value to operating cash flow ratio of -85.29 [5] - CSBR's debt-to-equity ratio is about 1.62, indicating reliance on debt financing, while a current ratio of approximately 0.94 suggests a need for improved short-term financial stability [5] - Despite these challenges, CSBR's earnings yield stands at approximately 4.12%, indicating a reasonable return on investment [5][6]